AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03031249
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ATO at a dose of 10mg/d on day 1-14
Trial: NCT00551421
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg solution, single intravenous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg solution, single subcutaneous injection
Trial: NCT00916110
Drug: ATN-103
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg solution, single intravenous injection
Trial: NCT02192632
Drug: Epiduo once daily with detailed instruction for how to apply it
RxNorm normalized name: Epiduo
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02192632
Drug: BPO once daily
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00360191
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01905566
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75mg once a day
Trial: NCT01905566
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90mg twice a day
Trial: NCT00418119
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00856687
Drug: PF-03893787
RxNorm normalized name: PF-03893787
DrugBank: Adriforant (DB15027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, two doses 12 hours apart
Trial: NCT00856687
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, two doses 12 hours apart
Trial: NCT00681941
Drug: Sevelamer carbonate (Renvela®)
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer Carbonate Tablets Dosed Three Times A Day
Trial: NCT03185793
Drug: benzbromarone
RxNorm normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
Trial: NCT01332552
Drug: GSK2485852 70 mg + Ritonavir 100mg
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose, day 1
Trial: NCT01332552
Drug: GSK2485852 210 mg + Ritonavir 100mg
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose, day 1
Trial: NCT01332552
Drug: GSK2485852 210 mg +Ritonavir 100mg
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose daily for 3 days
Trial: NCT02056847
Drug: Pitavastatin calcium 4mg
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: taking once a day
Trial: NCT02056847
Drug: Pitavastatin calcium 2mg
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taking once a day
Trial: NCT01450007
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 ml ropivacaine 0.5%
Trial: NCT01450007
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg dexamethasone (perineural)
Trial: NCT01450007
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
Trial: NCT00599196
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Trial: NCT02315118
Drug: T-cell therapy + Rituximab + IL-2
RxNorm normalized name: CD4CAR T cells
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients
Trial: NCT01131546
Drug: Levamlodipine besylate
RxNorm normalized name: Levamlodipine besylate
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 7AM - 10AM
Trial: NCT01131546
Drug: Amlodipine maleate
RxNorm normalized name: Amlodipine Maleate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, 7AM - 10AM
Trial: NCT01548911
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01118793
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg dosage of Clopidogrel for 7 to 10 days.
Trial: NCT01332266
Drug: E7050
RxNorm normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7050 given orally at 200, 300, or 400 mg once daily.
Trial: NCT01332266
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
Trial: NCT03302091
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 day treatment period
Trial: NCT00615368
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
Trial: NCT01529944
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Trial: NCT01536704
Drug: Nicotine (2 mg)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine lozenge in two formulations
Trial: NCT01536704
Drug: Nicotine (4 mg)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine lozenge in two formulations
Trial: NCT03770039
Drug: Oral PF-06700841 containing 14C microtracer
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
Trial: NCT03770039
Drug: Oral unlabeled PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg unlabeled PF-06700841 oral dose in 2nd period
Trial: NCT03770039
Drug: IV 14C-labeled PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
Trial: NCT01404000
Drug: Iodinated Active Charcoal (IodoCarb)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g will be given as an oral suspension once daily for 56 days
Trial: NCT00098137
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01337752
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous injection
Trial: NCT01337752
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01179100
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
Trial: NCT00669474
Drug: Treatment with Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Treatment with Botox
Trial: NCT02431442
Drug: RM-493
RxNorm normalized name: morphine sulfate Rectal Suppository [RMS]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02575365
Drug: 0,5 mg Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5 mg p.o fingolimod daily
Trial: NCT03431402
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
Trial: NCT02983188
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine tablets, 0.3g every time, two times daily
Trial: NCT02301806
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 50 mg tablet by mouth 12 weeks
Trial: NCT02301806
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride 1 mg tablet by mouth 12 weeks
Trial: NCT00431054
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
Trial: NCT00431054
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 by vein over 1 hour every 4 weeks
Trial: NCT00513383
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
Trial: NCT00513383
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
Trial: NCT00513383
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
Trial: NCT00513383
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
Trial: NCT00513383
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles
Trial: NCT00513383
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles
Trial: NCT00526812
Drug: RTA 744
RxNorm normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
Trial: NCT00526812
Drug: RTA 744 injection
RxNorm normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
Trial: NCT00256269
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/m2 IV over 60 minutes Every 21 days
Trial: NCT00256269
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
Trial: NCT01921712
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized single dose of inhaled active comparator product
Trial: NCT03616574
Drug: LONSURF
RxNorm normalized name: Lonsurf
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
Trial: NCT00830856
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 800mg po qday
Trial: NCT00830856
Drug: Fixed dose - Stavudine, lamivudine and Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
Trial: NCT00830856
Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
Trial: NCT03863405
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
Trial: NCT01336842
Drug: Panobinostat, Cisplatin, Pemetrexed
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
Trial: NCT03068312
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IVA 150 mg tablet.
Trial: NCT03210324
Drug: Mifepristone tablets
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
Trial: NCT01755559
Drug: Artesunate-amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antimalarial ACT
Trial: NCT01755559
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antimalarial ACT
Trial: NCT02404844
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral
Trial: NCT03466983
Drug: Iron Isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered IV
Trial: NCT03466983
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered IV
Trial: NCT00343083
Drug: Erbitux, Paclitaxel & Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)
Trial: NCT00454194
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: given IV
Trial: NCT00454194
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT00686829
Drug: Vicriviroc maleate
RxNorm normalized name: maleate
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCV 30 mg tablet once daily by mouth.
Trial: NCT01037179
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00134706
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
Trial: NCT00134706
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
Trial: NCT02875132
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab at 200mg IV infusion every 3 weeks
Trial: NCT03792100
Drug: SmofKabiven emulsion for infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition
Trial: NCT03792100
Drug: Hospital compounded All in one emulsion
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition
Trial: NCT00877487
Drug: SPD489 (Lisdexamfetamine dimesylate)
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
Trial: NCT03829254
Drug: NUC-7738
RxNorm normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-7738
Trial: NCT03829254
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab
Trial: NCT03314259
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population